DATE – Talk Bio

2025 FDA staff cuts and their impact on new drug review timelines

4 days ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

4 days ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

4 days ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

4 days ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

4 days ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

4 days ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

Crinetics Reports Over $5M in Q4 2025 PALSONIFY Revenue with Strong Launch Metrics

6 days ago talkbio0Tagged Acromegaly, Crinetics, enrollment forms, methionine, PALSONIFY, prescribers, Q4 2025, Revenue

Crinetics; PALSONIFY; Palsonify; Q4 2025; revenue; $5M; acromegaly; enrollment forms; prescribers

Novo Nordisk Launches Wegovy Pill in the US with Broad Availability

6 days ago talkbio0Tagged Glucagon-Like Peptide 1, January 2026, Novo Nordisk, Oral cavity, U.S., Wegovy pill, Weight Loss

Novo Nordisk; Wegovy pill; US launch; January 2026; oral GLP-1; weight loss

Spotlight On: Five key oncology stories to watch in 2026

6 days ago talkbio0Tagged 2026, Antibody-Drug Conjugates, cancer research trends, CAR-T, Cell Therapy, Liquid Biopsy, Lymphocytes, Tumor-Infiltrating, mRNA cancer, Neoplasms, oncology decisions, precision oncology, Radiopharmaceuticals, T-Cell Receptor, United States Food and Drug Administration, Vaccines

oncology 2026; cancer research trends; FDA oncology decisions 2026; antibody-drug conjugates; radiopharmaceuticals; liquid biopsy; mRNA cancer vaccines; AI in oncology; cell therapies CAR-T TIL TCR; precision oncology